Changes in safety laboratory parameters from baseline by the Food and Drug Administration (FDA) toxicity grading scale.;Geometric Mean Fold Rise (GMFR) of binding antibodies (IgG) by ELISA;Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Antibody;GMT of neutralizing antibody (pseudoviral neutralization assay) against Omicron and Delta variants of SARS-CoV-2;GMT of of neutralizing antibody (pseudoviral neutralization assay) against Wuhan strain;GMT of serum binding antibodies (IgG) by ELISA;Number of subjects with SAEs, SUSARs, MAAEs and AESIs;Number of subjects with solicited adverse events;Number of subjects with solicited systemic adverse events;Number of subjects with unsolicited adverse events;Seroresponse rate for binding antibodies (IgG) by ELISA;Seroresponse rate for neutralizing antibody

Changes in safety laboratory parameters from baseline by the Food and Drug Administration (FDA) toxicity grading scale.;Geometric Mean Fold Rise (GMFR) of binding antibodies (IgG) by ELISA;Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Antibody;GMT of neutralizing antibody (pseudoviral neutralization assay) against Omicron and Delta variants of SARS-CoV-2;GMT of of neutralizing antibody (pseudoviral neutralization assay) against Wuhan strain;GMT of serum binding antibodies (IgG) by ELISA;Number of subjects with SAEs, SUSARs, MAAEs and AESIs;Number of subjects with solicited adverse events;Number of subjects with solicited systemic adverse events;Number of subjects with unsolicited adverse events;Seroresponse rate for binding antibodies (IgG) by ELISA;Seroresponse rate for neutralizing antibody